Patents by Inventor Matthew Cooper
Matthew Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240245988Abstract: A convenient system with replacement hardware is provided for rendering scents within a computing environment. In some implementations, a scent cartridge unit is provided that is replaceable within a scent-rendering hardware unit that is computer-controlled to render one or more scents to be experienced by a user. The scent-rendering hardware unit includes one or more aerosol generators that are adapted to release individual scents. In some implementations, more than one scent may be released at the same time, rendering a complex scent. In some implementations, base scent material may be provided within multiple aerosol generators within an array, and the base scent material may be released in predetermined amounts, durations, and intensities depending on the desired scent. The array may be electronically driven by signals provided by driver circuitry.Type: ApplicationFiled: January 26, 2024Publication date: July 25, 2024Applicant: OVR Tech, LLCInventors: Erik Cooper, Aaron Wisniewski, Matthew Flego, Samuel Wisniewski
-
Patent number: 12046881Abstract: An intelligent electrical conductor installation system includes a puller sub-system, a tensioner sub-system, and a running board. The pull sub-system is configured to provide a pulling force to a pull rope connected on one end to the running board. The tensioner sub-system is configured to provide tension to the one or more conductors connected to the running board during installation of the conductors. The running board is connected to the pull rope on a first end, and configured to be connected to one or more conductors on a second end, wherein the running board includes one or more sensors configured to sense attributes of the conductor pull operation.Type: GrantFiled: January 28, 2019Date of Patent: July 23, 2024Assignee: Sherman + Reilly, Inc.Inventors: Douglas Bruce MacDonald, Harby Carter Hollis, Ryan Arthur Berg, Matthew Caleb Faircloth, Joshua Cooper Collins, Toni Corinne Tran
-
Patent number: 12030879Abstract: The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; R2 is a cyclic group substituted at the a and a? positions, wherein the substituent at the ?-position is a monovalent heterocyclic group or a monovalent aromatic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently optionally substituted C1-C4 alkyl.Type: GrantFiled: March 1, 2019Date of Patent: July 9, 2024Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Jimmy Van Wiltenburg, Johannes Wilhem Georg Meissner, Jochem Theodoor Van Herpt, Zhou Min Lion, Jonathan Shannon, Stephen St-Gallay
-
Patent number: 12012392Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising as-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: November 9, 2018Date of Patent: June 18, 2024Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Angus Macleod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Ian Strutt
-
Publication number: 20240189355Abstract: The present disclosure provides compositions of genetically modified cells that are hypoimmunogenic. The present disclosure also provides methods of making hypoimmunogenic cells and using hypoimmunogenic cells for the treatment of cancer and autoimmune conditions.Type: ApplicationFiled: November 14, 2023Publication date: June 13, 2024Inventors: You ZHOU, Matthew COOPER, Elizabeth SCHRAMM
-
Patent number: 12002480Abstract: A method for representing a second presentation of audio channels or objects as a data stream, the method comprising the steps of: (a) providing a set of base signals, the base signals representing a first presentation of the audio channels or objects; (b) providing a set of transformation parameters, the transformation parameters intended to transform the first presentation into the second presentation; the transformation parameters further being specified for at least two frequency bands and including a set of multi-tap convolution matrix parameters for at least one of the frequency bands.Type: GrantFiled: July 13, 2023Date of Patent: June 4, 2024Assignees: Dolby Laboratories Licensing Corporation, Dolby International ABInventors: Dirk Jeroen Breebaart, David Matthew Cooper, Leif Jonas Samuelsson
-
Publication number: 20240173407Abstract: The present disclosure provides chimeric receptor constructs comprising a CD3e extracellular domain and engineered NK and T cells expressing such receptors and methods of making and using same for the treatment of cancer and other diseases of the immune system.Type: ApplicationFiled: November 3, 2023Publication date: May 30, 2024Inventors: You ZHOU, Elizabeth SCHRAMM, Matthew COOPER
-
Patent number: 11981667Abstract: The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: August 16, 2022Date of Patent: May 14, 2024Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Angus MacLeod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
-
Publication number: 20240150428Abstract: Disclosed herein are genome-edited invariant natural killer T (iNKT) cells and methods of immunotherapy using them. In particular, the disclosure relates to engineered chimeric antigen receptor (CAR)-bearing INKT cells (CAR-iNKTs) and methods of using the same for the treatment of cancer.Type: ApplicationFiled: June 23, 2023Publication date: May 9, 2024Inventors: John DiPersio, Matthew Cooper, Julie O'Neal
-
Publication number: 20240141399Abstract: Provided herein are methods for generating multiplex CRISPR arrays based on annealing and ligating single-stranded DNA oligonucleotides using bridge oligonucleotides. The methods described herein include providing a first oligonucleotide comprising a CRISPR repeat sequence or a portion thereof, and a first portion of a first spacer sequence at its 3? end; providing a second oligonucleotide comprising, from 5? to 3?, a second portion of the first spacer sequence, the CRISPR repeat sequence, and a first portion of a second spacer sequence; providing a bridge oligonucleotide comprising a sequence substantially complementary to the first spacer sequence; allowing the first oligonucleotide and the second oligonucleotide to hybridize with the bridge oligonucleotide; and ligating the first and second oligonucleotide.Type: ApplicationFiled: February 28, 2022Publication date: May 2, 2024Inventors: Robert Matthew Cooper, Jeff Hasty
-
Patent number: 11950078Abstract: Methods for dialogue enhancing audio content, comprising providing a first audio signal presentation of the audio components, providing a second audio signal presentation, receiving a set of dialogue estimation parameters configured to enable estimation of dialogue components from the first audio signal presentation, applying said set of dialogue estimation parameters to said first audio signal presentation, to form a dialogue presentation of the dialogue components; and combining the dialogue presentation with said second audio signal presentation to form a dialogue enhanced audio signal presentation for reproduction on the second audio reproduction system, wherein at least one of said first and second audio signal presentation is a binaural audio signal presentation.Type: GrantFiled: April 28, 2023Date of Patent: April 2, 2024Assignees: Dolby Laboratories Licensing Corporation, DOLBY INTERNATIONAL ABInventors: Leif Jonas Samuelsson, Dirk Jeroen Breebaart, David Matthew Cooper, Jeroen Koppens
-
Publication number: 20240105186Abstract: A method for encoding an input audio stream including the steps of obtaining a first playback stream presentation of the input audio stream intended for reproduction on a first audio reproduction system, obtaining a second playback stream presentation of the input audio stream intended for reproduction on a second audio reproduction system, determining a set of transform parameters suitable for transforming an intermediate playback stream presentation to an approximation of the second playback stream presentation, wherein the transform parameters are determined by minimization of a measure of a difference between the approximation of the second playback stream presentation and the second playback stream presentation, and encoding the first playback stream presentation and the set of transform parameters for transmission to a decoder.Type: ApplicationFiled: October 16, 2023Publication date: March 28, 2024Applicants: DOLBY LABORATORIES LICENSING CORPORATION, DOLBY INTERNATIONAL ABInventors: Dirk Jeroen Breebaart, David Matthew Cooper, Leif Jonas Samuelsson, Jeroen Koppens, Rhonda J. Wilson, Heiko Purnhagen, Alexander Stahlmann
-
Patent number: 11926600Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a monocyclic imidazolyl group of formula (I): wherein Q is selected from O or S, R1 is an imidazolyl group, wherein the imidazolyl group is unsubstituted or substituted with one or more monovalent substituents, and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: August 15, 2018Date of Patent: March 12, 2024Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Angus MacLeod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
-
Publication number: 20240075141Abstract: Among the various aspects of the present disclosure is the provision of improved chimeric receptor constructs for NK cells, NK cells containing such receptors and methods of making and using same.Type: ApplicationFiled: March 17, 2023Publication date: March 7, 2024Inventors: You ZHOU, Matthew COOPER, Elizabeth SCHRAMM
-
Patent number: 11905252Abstract: The present invention relates to sulfonylureas and sulfonylthioureas of formula (I) comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, and wherein the group attached to the terminal nitrogen atom of the urea group is either a 1,2,3,5,6,7-hexahydro-s-indacen-4-yl group substituted at the 8-position, or a heteroaryl group substituted at the alpha and alpha? positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.Type: GrantFiled: March 1, 2019Date of Patent: February 20, 2024Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Angus Macleod, Jonathan Shannon
-
Publication number: 20240033357Abstract: The disclosure relates to chimeric antigen receptors and immune effector cells bearing chimeric antigen receptors (CARs). Disclosed herein are improved CARs that are able to recruit Lck and/or and PLC? without the need to express CD2, thereby providing efficient CAR function without the risk of CD2-induced fratricide; optionally, the CARs also comprise CD132. Further disclosed herein are improved CARs specific for CD2. Further disclosed herein are improved immune effector cells bearing such improved CARs, therapeutic compositions comprising such improved immune effector cells, and methods for treating cancer using such improved immune effector cells and/or therapeutic compositions.Type: ApplicationFiled: October 10, 2023Publication date: February 1, 2024Inventors: You W. ZHOU, Matthew COOPER, James P. WHITE
-
Patent number: 11884645Abstract: The present invention relates to compounds of formula (1): wherein Q is selected from O or S; R1 is a 5-membered nitrogen-containing heteroaryl group substituted with R6 and optionally further substituted; R2 is an alpha, alpha?-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3 to 7 membered saturated or unsaturated, optionally substituted cyclic group; R5 is independently an optionally substituted C1-C4 alkyl group; and R6 is any group comprising a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: March 1, 2019Date of Patent: January 30, 2024Assignee: INFLAZOME LIMITEDInventors: David Miller, Jimmy Van Wiltenburg, Matthew Cooper
-
Patent number: 11872626Abstract: Techniques for joining nodes and subcomponents are presented herein. An apparatus in accordance with an aspect of the present disclosure comprises a 3-D printed first part having an interconnect co-printed with the first part such that the interconnect of the first part can float within the first part, and a 3-D printed second part having an interconnect co-printed with the second part such that the interconnect of the second part can float within the second part, wherein the interconnects of the first and second parts are configured to form a connection between the first and second parts.Type: GrantFiled: November 5, 2021Date of Patent: January 16, 2024Assignee: DIVERGENT TECHNOLOGIES, INC.Inventors: Samuel Noah Miller, Matthew Cooper Keller, Eric Paul Monteith, Thomas Samuel Bowden, Jr.
-
Patent number: 11858922Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 or R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.Type: GrantFiled: February 16, 2017Date of Patent: January 2, 2024Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder, Angus Murray Macleod, David John Miller
-
Patent number: D1023679Type: GrantFiled: December 16, 2021Date of Patent: April 23, 2024Inventors: Lena Ripley, Matthew Cooper, Nick Hansen